Targeted delivery of PD‐L1‐derived phosphorylation‐mimicking peptides by engineered biomimetic nanovesicles to enhance osteosarcoma treatment

Wei Wu,Haoyu Guo,Doudou Jing,Zhenhao Zhang,Zhicai Zhang,Feifei Pu,Wenbo Yang,Xin Jin,Xin Huang,Zengwu Shao

DOI: https://doi.org/10.1002/adhm.202200955

IF: 10

2022-09-22

Advanced Healthcare Materials

Abstract:Osteosarcoma is a rare malignant bone‐originating tumor that usually occurs in young people. Programmed cell death 1 ligand 1 (PD‐L1), an immune checkpoint protein, is highly expressed in osteosarcoma tissues. Several recent studies have indicated that the tumor‐related role of PD‐L1 in tumors, especially non‐plasma membrane (NPM)‐localized PD‐L1, is not limited to immune regulation in osteosarcoma. Here, we combined mass spectrometry analysis with RNA‐seq examination to identify the intracellular binding partners of PD‐L1 and elucidate the underlying mechanism of its action. We found that NPM‐localized PD‐L1 interacted with Insulin‐like growth factor binding protein‐3 (IGFBP3) to promote osteosarcoma tumor growth by activating mTOR signaling. This interaction was enforced after phosphoglyceratekinase1 (PGK1)‐mediated PD‐L1 phosphorylation. Based on these findings, we designed a phosphorylation‐mimicking peptide from PD‐L1 and encapsulated it with a Cyclic RGD (cRGD)‐modified red blood cell membrane (RBCM) vesicle (Peptide@cRGD‐M). The Peptide@cRGD‐M precisely delivered the PD‐L1‐derived phosphorylation‐mimicking peptide into osteosarcoma lesions and significantly promoted its therapeutic effect on the tumor. Therefore, our investigation not only highlighted the function of NPM‐localized PD‐L1 but also used an engineering approach to synthesize a small molecular peptide capable of inhibiting osteosarcoma growth. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials